Cullinan Oncology (CGEM) 10-Q2024 Q2 Quarterly report

Filed: 8 Aug 24, 7:20am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Additionally, Advisor, advisory, age, amivantamab, announced, appointed, appointment, attention, attest, attestation, auditor, background, Bill, Bio, biotech, Boston, Cattolica, cease, Certified, Committee, copy, CPI, Cubist, Cuore, decline, del, devote, Dimension, director, divert, Entrada, exceeded, exceeding, Exhibit, fall, firm, gene, golden, heading, Homology, immunology, independent, injection, issuable, joining, leadership, longer, mandated, mandatory, Mary, median, Melinda, member, Neuroscience, Nominating, notified, oral, Oversight, parachute, pembrolizumab, PerkinElmer, person, post, preliminary, President, previously, proceeding, proposed, reclassification, rely, return, rheumatoid, Rome, rotation, Sacro, site, SRC, stockholder, substitution, Thistle, tyrosine, unexercised, Universit, unresponsive, ViaCell, Vice, Vigil, Ziopharm

Removed: acquired, advantage, Amber, anniversary, begin, billion, classification, closing, complying, determinable, dosed, Dr, earliest, enacted, fixed, Florentine, inclusive, liability, lymphoma, MICA, occur, occurrence, potency, redeemable, robust, serum

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CGEM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cullinan Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 8, 2024	By:	/s/ Nadim Ahmed
		Nadim Ahmed
		President and Chief Executive Officer (Principal Executive Officer)


Date: August 8, 2024	By:	/s/ Mary Kay Fenton
		Mary Kay Fenton
		Chief Financial Officer (Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.